Aung Naing

77PUBLICATIONS
250CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsImmunogenetics (incl. genetic immunology)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (77)

|Jun 24, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

|Jun 08, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

|May 08, 2026
Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

|Apr 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.

|Mar 26, 2026
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors.

Burak Uzunparmak, Fei Su, Amber Johnson

|Mar 07, 2026
Rate of Hearing Loss in Platinum-Naïve Patients Receiving Immune Checkpoint Inhibitors.

Kaitlyn A Brooks, Christopher G Gidley, Olivia Grimley

Pageof 13

Frequent Collaborators

15 joint publications

Vivek Subbiah

15 joint publications

Funda Meric-Bernstam

14 joint publications

Apostolia-Maria Tsimberidou

13 joint publications

Siqing Fu